
Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma 4 with BRAF V600E mutation as detected by an FDA-approved test.
Limitation of use: Dabrafenib is not indicated for treatment of patients with wild-type BRAF 6 melanoma .
from FDA,2013.05
Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts antitumor effects by specifically targeting the BRAF V600E/V600K mutation site. Developed by Novartis P···【more】
Article source:Lucius LaosRelease date:2026-03-19Recommended:50
Dabrafenib is a kinase inhibitor developed by Novartis Pharmaceuticals. It was first approved by the FDA for marketing on May 29, 2013. Dabrafenib inhibits the cell growth of vario···【more】
Article source:Lucius LaosRelease date:2026-03-19Recommended:35
Patients with unresectable or metastatic melanoma with BRAF V600E mutation.【more】
Article source:Lucius LaosRelease date:2026-01-06Recommended:35
Dabrafenib is an important therapeutic drug that plays a key role in the treatment of specific diseases. This article will detail the applicable populations for dabrafenib and its ···【more】
Article source:Lucius LaosRelease date:2025-01-10Recommended:258
Dabrafenib is a targeted therapy drug with a specific scope of application in clinical applications.What diseases is Laos Luciosdharafinil suitable forDabrafenib is mainly targeted···【more】
Article source:Lucius LaosRelease date:2025-01-10Recommended:291

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: